Geetha Kandavello @ Kandhavel Malaysia

Dr Geetha is a Senior Consultant Paediatric Cardiologist and Consultant Adult Congenital Heart Disesae. Her expertise is in Adult congenital heart disease; Pulmonary Hypertension; Cardio Obstetrics; and Marfan and Aortopathy. She is the immediate past President of the International Society of Adult Congenital Heart Disease and has served as the Chairman of the Malaysian Paediatric Cardiac Society. Dr Geetha was also involved in developing in Malaysia Clinical Practice Guidelines on Pulmonary Arterial Hypertension, Pregnancy and Heart Disease and Prevention and Management of Infective Endocarditis. Dr Geetha is a member of the National Confidential Enquiries into Maternal Death in Malaysia and a faculty member for the Cardio-Obstetrics Masterclass India. She is also the advisor for Pulmonary Hypertension Association Malaysia and executive member of the Malaysian Congenital Heart Foundation.
Job Title
Senior Consultant Paediatric Cardiologist
Faculty / Department / Division
Paediatric & Congenital Heart Centre
Institution / Organisation
National Heart Institute

21 November 2026, Saturday

Time Session
11:00
12:30
Chai Chan Sin Chairperson Malaysia
Fatimah Azmah Mohammad Chairperson Malaysia
  • Parth Rali Speaker United States
  • Luis Jara-Palomares Speaker Spain
    Chronic thromboembolic pulmonary hypertension (CTEPH) is a potentially treatable cause of pulmonary hypertension characterised by persistent organised pulmonary arterial obstruction and secondary microvascular remodelling. Despite advances in management, delayed recognition and unequal access to expert care remain important challenges. This presentation reviews the contemporary diagnostic and therapeutic pathway, integrating guideline recommendations with evidence from clinical trials and international registries. Persistent dyspnoea or exercise limitation after pulmonary embolism should prompt structured assessment, while the absence of a recognised embolic event does not exclude CTEPH. Ventilation–perfusion imaging, anatomical assessment and right heart catheterisation provide complementary information for diagnosis and treatment planning. Multidisciplinary evaluation is central to selecting pulmonary endarterectomy, balloon pulmonary angioplasty and medical therapy. Lifelong therapeutic anticoagulation remains essential, although uncertainty persists regarding the optimal anticoagulant for patients without antiphospholipid syndrome. Symptomatic chronic thromboembolic pulmonary disease without resting pulmonary hypertension requires careful symptom attribution and individualised treatment decisions. Future developments include circulating biomarkers, novel therapies targeting vascular remodelling and artificial intelligence for earlier detection, complication prediction and phenotyping. Multimodal models integrating clinical, biochemical and imaging data could support diagnostic testing and referral decisions, but require external validation and prospective demonstration of clinical benefit. Earlier recognition, timely expert referral and individualised multimodal care remain the priorities for improving outcomes.
  • Q&A
Ballroom 3, Lower Ground Floor